<DOC>
	<DOCNO>NCT02644447</DOCNO>
	<brief_summary>Cellular therapy rapidly progress field show immense promise treatment damage ovarian function . The purpose study determine safety efficacy intra-ovarian injection allogeneic HUC-MSCs injectable collagen scaffold woman Premature Ovarian Failure ( POF ) study preliminary efficacy HUC-MSCs injectable collagen scaffold injection ovarian function improvement .</brief_summary>
	<brief_title>Transplantation HUC-MSCs With Injectable Collagen Scaffold POF</brief_title>
	<detailed_description>The purpose study explore therapeutic potency HUC-MSCs injectable collagen scaffold transvaginal injection POF woman . The serum patient keep sent laboratory test surgery . HUC-MSCs isolate cultured vitro biomarkers HUC-MSCs detect use Flow cytometry detection . The HUC-MSCs injectable collagen scaffold inject directly bilateral ovary . The outcomes patient examine injection . The patient monitor sign follicle growth grow follicle stimulate exogenous hormone , follow oocyte retrieval In Vitro Fertilization ( IVF ) .</detailed_description>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Primary Ovarian Insufficiency</mesh_term>
	<mesh_term>Menopause , Premature</mesh_term>
	<criteria>1 . Diagnosed Premature Ovarian Failure . 2 . Patients show response drug treatment 3 . Women 20 39 year . 4 . Willing sign Informed Consent Form . 1 . Abnormal karyotyping ( e.g . turner syndrome , fragile X syndrome ) . 2 . Congenital ovarian malformation . 3 . Severe endometriosis . 4 . Thyroid dysfunction . 5 . Contraindications pregnancy . 6 . Contraindications hormone replacement therapy . 7 . Prior personal history ovarian cancer radiotherapy . 8 . Unwilling comply followup schedule want take treatment followup period .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>